Resolutions at Senzime AB’s (publ) annual general meeting

Senzime AB (publ) (the “Company”) held its annual general meeting on May 8, 2018 in the Company’s premises on Ulls väg 29B in Uppsala.

A. Annual report and results

The general meeting adopted the income statement and the balance sheet for the financial year 2017 and resolved, in accordance with the board of director’s proposal, that the result according to the approved income statement would be transferred on a new account. No dividend distribution.

B. Discharge from liability

The general meeting granted the board members of the board of directors and the managing director discharge from liability for the management of the Company’s business for the financial year 2017.

C. Board and auditor remuneration

The general meeting resolved that the board should be remunerated as follows: SEK 100,000 to the chairman of the board and SEK 50,000 to each of the other board members. However, it was also resolved that no remuneration will be paid to a board member if he/she, during the financial year 2018, has received more than twice his/her remuneration as consultancy fees from the Company.

The general meeting further decided that auditor should be remunerated in accordance with approved invoices.

D. Election of board and auditor

The general meeting resolved that the board of directors should consist of five directors and that no deputy directors shall be appointed.

The general meeting resolved, up until the end of the next annual general meeting, to re-elect Adam Dahlberg, Philip Siberg, Ulf Lindskog and Sorin Brull as board members and to elect Lennart Kalén as new board member. Philip Siberg was re-elected as the chairman of the board of directors.

It was decided to re-elect PricewaterhouseCoopers AB, with Leonard Daun as chief auditor until the annual general meeting 2019.

E. Nomination committee for the annual general meeting 2019

The general meeting resolved to adopt principles for the appointment of the nomination committee for the annual general meeting 2019. It was decided that the members of the Nomination Committee for the 2019 annual general meeting will be composed of representatives of the three largest shareholders together with the chairman of the board.

F. Authorization

The general meeting resolved to authorize the board of directors – for the period up to the next annual general meeting – to issue shares, warrants and/or convertible instruments. The authorization may be used with deviation from the shareholders’ pre-emption rights and/or an issue in kind of by way of set-off (or otherwise on terms set out in the Swedish Companies Act). The authorization may be used to increase the Company’s share capital with maximum SEK 560,761.

All resolutions at the annual general meeting were adopted with required majority.

For further information, please contact:

Lena Söderström, CEO of Senzime AB

Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com 

————————————

Senzime AB (publ)

Board of directors

TO THE EDITORS  

About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com  

Tags:

About Us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com

Subscribe

Documents & Links